Literature DB >> 10080218

Central nervous system symptoms in patients with Behçet disease receiving cyclosporine therapy.

S Kotake1, K Higashi, K Yoshikawa, Y Sasamoto, T Okamoto, H Matsuda.   

Abstract

OBJECTIVE: To investigate the association between the development of central nervous system (CNS) symptoms in patients with Behçet disease and medical therapy.
DESIGN: Retrospective cohort study. PARTICIPANTS: A total of 317 patients with Behçet disease with ocular complications who visited Hokkaido University Hospital, Sapporo, Japan, between 1978 and 1994. MAIN OUTCOME MEASURES: The incidence of CNS symptoms in different medical therapies.
RESULTS: Twenty-one (6.6%) of the 317 patients developed CNS symptoms, namely neuro-Behçet disease. Of the 21 patients, 12 were undergoing cyclosporine therapy. Of the 47 patients who underwent cyclosporine therapy, 12 (25.5%) developed CNS symptoms, whereas only 9 (3.3%) of 270 patients who did not undergo cyclosporine therapy developed CNS symptoms.
CONCLUSIONS: Cyclosporine in the treatment of Behçet disease appears to cause neurotoxicity or to accelerate the development of CNS symptoms. Thus, neurologic complications appear to represent a major side effect of cyclosporine in the treatment of patients with Behçet disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10080218     DOI: 10.1016/S0161-6420(99)90120-3

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  30 in total

1.  Behçet's Disease.

Authors: 
Journal:  Curr Treat Options Neurol       Date:  2000-09       Impact factor: 3.598

2.  A case of tuberculous meningoencephalitis in a patient with Behçet's disease.

Authors:  Alexios Iliopoulos; Simeon Kedikoglou; Stefanos Laxanis; Spiros Kourouklis; Evagelos Katsaros
Journal:  Clin Rheumatol       Date:  2005-05-18       Impact factor: 2.980

Review 3.  Standard and novel therapeutic approaches to Behçet's disease.

Authors:  Ahmet Gul
Journal:  Drugs       Date:  2007       Impact factor: 9.546

4.  Behçet's Disease.

Authors:  Gulsen Akman-Demir; Sabahattin Saip; Aksel Siva
Journal:  Curr Treat Options Neurol       Date:  2011-06       Impact factor: 3.598

Review 5.  Update on the therapy of Behçet disease.

Authors:  Zeinab Saleh; Thurayya Arayssi
Journal:  Ther Adv Chronic Dis       Date:  2014-05       Impact factor: 5.091

Review 6.  Pediatric Behçet's disease - clinical aspects and current concepts.

Authors:  Mehmet Yıldız; Oya Köker; Amra Adrovic; Sezgin Şahin; Kenan Barut; Özgür Kasapçopur
Journal:  Eur J Rheumatol       Date:  2019-09-05

Review 7.  Behçet syndrome: from pathogenesis to novel therapies.

Authors:  Gianluigi Mazzoccoli; Angela Matarangolo; Rosa Rubino; Michele Inglese; Angelo De Cata
Journal:  Clin Exp Med       Date:  2014-12-02       Impact factor: 3.984

Review 8.  The spectrum of nervous system involvement in Behçet's syndrome and its differential diagnosis.

Authors:  Aksel Siva; Sabahattin Saip
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

Review 9.  Behcet's Syndrome.

Authors:  Sam R Dalvi; Resit Yildirim; Yusuf Yazici
Journal:  Drugs       Date:  2012-12-03       Impact factor: 9.546

Review 10.  Behçet Disease: An Update for Dermatologists.

Authors:  Erkan Alpsoy; Burcin Cansu Bozca; Asli Bilgic
Journal:  Am J Clin Dermatol       Date:  2021-06-01       Impact factor: 7.403

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.